Ubiquitin Regulation of K Channels in Health and Disease

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2018
    2021
  • Known Financial Commitments (USD)

    $337,499
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    COLUMBIA UNIVERSITY HEALTH SCIENCES
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SummaryThis proposal is for a COVID-19-related Administrative Supplement for RO1HL142111, "Ubiquitin regulation ofK Channels in Health and Disease". We propose to adapt/apply tools and approaches including, nanobodydevelopment and optical assays of membrane proteins, that we have developed for studies in the parent proposalto develop novel solutions for COVID-19. There is an ongoing global pandemic in which a novel Coronavirus,SARS-CoV-2, causes Coronavirus Disease-2019 (COVID-19) that is lethal to a subset of the infected population.To date, there are >1.5 million confirmed COVID-19 cases worldwide with >70,000 fatalities. In the United States,best case scenario projections indicate 100,000 - 240,000 lives will be lost to COVID-19, with a worst casescenario of >2 million deaths. The current pandemic follows two other regional outbreaks of coronavirusesresponsible for severe acute respiratory syndrome (SARS-CoV) in 2002, and Middle Eastern respiratorysyndrome (MERS-CoV) in 2012, that caused epidemics with fatality rates of 10% and 36%, respectively. All threecoronaviruses represent examples of animal to human transmission of infection. Given a high zoonotic reservoirof novel coronaviruses and persistence of close animal/human contact in various parts of the world, the chancesof future viral epidemics/pandemics beyond the current crisis is high. Hence, fatal diseases caused by viralinfections represent current and future widespread public health challenges, highlighting an urgent need forgeneral strategies that can combat not only COVID-19 but also other future viral outbreaks. SARS-CoV-2 is anenveloped virus that gains access to host cells by using a receptor binding domain (RBD) on a viral surface spikeprotein (S) to bind to membrane-bound angiotensin-converting enzyme 2 (ACE2) receptors on target cells.Preventing the SARS-CoV-2 S protein/ACE2 receptor interaction is the main principle behind the beneficialeffects of neutralizing antibodies in recovered patients, and the scientific premise for an ongoing clinical trial foradministration of soluble ACE2 ectodomain. There are ongoing efforts to develop neutralizing monoclonalantibodies (mAb) against SARS-CoV-2 S protein that disrupt interaction with ACE2. While potentially effective,limitations of this approach include high cost, time-consuming, incompatibility with inhalation formulations, andpotential for viral mutations that result in escape from mAb-mediated neutralization. This proposal is based onthe hypothesis that engineered single-domain antibodies (nanobodies) with high avidity for SARS-CoV-2 Sprotein can be generated to overcome some of the limitations of neutralizing mAbs and provide potentialtherapeutic leads for COVID-19. We propose three aims: 1) Isolate and characterize neutralizing and non-neutralizing nanobodies against SARS-CoV-2 S protein; 2) Develop cell-based high throughput fluorescenceassay to probe SARS-CoV-2 S protein/ACE2 interaction and internalization; 3) Comparatively evaluate thecapacity of engineered nanobodies to disrupt SARS-CoV-2 S protein/ACE2 interaction and internalization